What Is Pinealon?

Published August 2026 · Patriot Labs Research Team · ~10 min read

What Pinealon is

Pinealon is a synthetic tripeptide: three amino acids joined by two peptide bonds. The sequence is glutamic acid – aspartic acid – arginine, written Glu-Asp-Arg in three-letter code and EDR in one-letter code. Chemical catalogues list it under CAS 175175-23-2, molecular formula C₁₅H₂₆N₆O₈, molecular weight approximately 418.4 Da.

Two names for one molecule is a recurring source of confusion here. The commercial and vendor-facing name is Pinealon. The name used across most of the primary literature is the EDR peptide. A 2021 review in Molecules states the identity explicitly and adds a detail worth knowing: EDR was described as having been isolated from Cortexin, a bovine cortex-derived preparation used clinically in Russia. So the molecule was not designed from a target structure — it was pulled out of a tissue extract, and the tissue of origin is where the “neuro” framing comes from.

Search only for “Pinealon” and you will miss most of the science; search only for “EDR peptide” and you will pick up unrelated hits, because those three letters mean many things. That asymmetry is small, but it explains why so much of the secondary writing about this compound is inaccurate.

The chemistry of a tripeptide

It is worth pausing on how small this molecule is. At roughly 418 Da, Pinealon is smaller than many small-molecule drugs and roughly one-third the mass of BPC-157. Against a 15-residue peptide, a 43-residue peptide or a 39-residue GLP-1 analogue, the difference is not incremental — it is a difference in what kind of object you are dealing with.

Chemically, two of the three residues (Glu, Asp) carry negative charge at physiological pH and one (Arg) carries positive charge, giving a net charge near −1 and a strongly hydrophilic character. That matters for two reasons that pull in opposite directions. Highly charged, hydrophilic molecules do not passively cross lipid bilayers well — which is a problem for any mechanism that requires the peptide to be inside the cell. But the same charge distribution is exactly what you would want if you were arguing for electrostatic contact with the phosphate backbone of DNA or with basic histone proteins.

A peptide this short also has essentially no secondary structure in solution — it is a flexible string, not a folded object with a binding surface. Conventional receptor pharmacology depends on a ligand presenting a defined shape to a defined pocket. Pinealon has none, which is part of why its proposed mechanism is not receptor-based at all.

The bioregulator framework

Pinealon does not stand alone. It is one member of a family of short peptides — Vilon (Lys-Glu), Vesugen (Lys-Glu-Asp), Epithalon (Ala-Glu-Asp-Gly), Pinealon (Glu-Asp-Arg) and others — developed over several decades at the St Petersburg Institute of Bioregulation and Gerontology, largely under Vladimir Khavinson. The family is usually called the peptide bioregulators or, in vendor writing, the Khavinson peptides.

The programme's organising idea is that each tissue produces its own characteristic short peptides, that these act as tissue-specific regulators of gene expression, and that supplying a synthetic copy can restore an aging or stressed tissue's own regulatory signalling. Each peptide is therefore assigned a target tissue: Epithalon to the pineal gland, Pinealon to the brain, others to thymus, prostate, vasculature and so on.

Epithalon is the better-known member of the family — the tetrapeptide the framework is usually argued from, with the larger literature, and the one that appears in most discussions of peptides studied in anti-aging research. Pinealon is the neural counterpart, and the two are frequently discussed together because the proposed mechanism is identical; only the assigned tissue differs.

The framing point that matters: Pinealon's plausibility is largely inherited. Very little of the case for it rests on Pinealon-specific evidence. Most of it rests on whether the bioregulator framework as a whole is correct.

The proposed mechanism, step by step

The hypothesis is worth laying out cleanly, because it is usually either dismissed without description or repeated without scrutiny. As stated in the programme's own reviews, it has four links:

1. The peptide gets into the cell. A 2022 paper in the International Journal of Molecular Sciences proposes that ultrashort peptides are carried across the membrane by proton-dependent oligopeptide transporters of the SLC15 family (PEPT1, PEPT2, PHT1, PHT2) and by SLC7-family amino-acid exchangers. The work is molecular modelling and docking plus literature synthesis, not direct transport measurement, and the authors say so — they state that transport of ultrashort peptides into the cell has not been properly studied yet.

2. The peptide gets into the nucleus. Our database search turned up a 2011 report in Biochemistry (Moscow) titled “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells…”. We were not able to retrieve its full text, so we can speak only to what the title establishes: the experiment used labelled peptides in HeLa cells. Two structural caveats follow from that alone — HeLa is a cancer line with atypical nuclear transport behaviour, and fluorophore conjugation substantially changes a 418 Da molecule.

3. The peptide contacts DNA or chromatin. The 2021 Molecules review reports that EDR interacts with DNA in vitro with a destabilising effect on secondary structure, proposing binding at the d(CCTGCC)₂ and d(CCAGC)₂ sequences. A 2019 study in The Journal of Physical Chemistry B examined the role of mono- and divalent ions in the Glu-Asp-Arg–DNA interaction — which at least places part of this work in a discipline with harder measurement standards. A 2021 systematic review from the same group describes EDR contacting the major groove of double-stranded DNA and binding histone H1.3.

4. Gene expression changes. Predicted binding sites have been reported in the promoter regions of PPARA, PPARG, SOD2, GPX1 and TPH1. The TPH1 claim is the one with a matching functional readout: a 2014 study in Bulletin of Experimental Biology and Medicine reported that Glu-Asp-Arg and Lys-Glu-Asp stimulated serotonin expression in aging brain-cortex cell cultures, with molecular docking used to argue that the CCTGCC motif in the tryptophan hydroxylase gene is complementary to the peptides.

That is the chain. Each link has something behind it. What does not exist, as far as we can find, is a single independent experiment that demonstrates the whole chain for Pinealon — uptake, nuclear localisation, site-specific chromatin contact, and the resulting transcriptional change — in one system.

Why “tissue-specific tripeptide” is a strong claim

This is the part that deserves to be argued fairly rather than waved away, in either direction.

The objection is combinatorial. There are only 8,000 possible tripeptides from the twenty standard amino acids, and Glu-Asp-Arg is not a rare motif: it occurs inside countless proteins as an ordinary stretch of sequence and is generated routinely by proteolysis. A Europe PMC search for the string returns hundreds of records, most about flaxseed protein isolates, shrimp-paste starters, tea-plant amino acid mapping and similar — the motif turning up incidentally in unrelated biochemistry. If three residues were sufficient to direct a tissue-specific transcriptional programme, it is not obvious why the same string arising constantly from ordinary protein turnover would not do the same.

There is a coherent reply, and it should be stated. The programme's position is that specificity comes not from the peptide alone but from the combination of the peptide, the transporter repertoire of a given cell type, and which chromatin regions are accessible in that cell at that time. On this account a tripeptide is not a key that opens one lock; it is a small perturbation whose effect is determined almost entirely by the state of the system it enters. That is not an incoherent model — small charged molecules do modulate chromatin, and cell-type-specific accessibility is well established.

The trouble is that this reply also makes the claim harder to falsify, and raises the evidentiary bar rather than lowering it. If specificity is contextual, demonstrating it requires exactly the study that is missing: matched cell types, proper controls including scrambled and single-residue-substituted peptides, direct measurement of intracellular peptide, and chromatin occupancy measured rather than modelled. Docking against a promoter sequence predicts what could bind. It does not show what does.

Our honest read: the mechanism is not absurd, it is under-demonstrated. Those are different criticisms and it is worth keeping them apart.

What has actually been studied

Here is what we could actually retrieve, described by model rather than by conclusion.

Oxidative stress in cultured cells. A 2011 paper in Rejuvenation Research tested Pinealon in rat cerebellar granule cells, rat PC12 pheochromocytoma cells and neutrophils under receptor-dependent and receptor-independent oxidative stress. Reported outcomes: concentration-dependent suppression of reactive oxygen species accumulation, reduced necrotic cell death by propidium iodide staining, ERK 1/2 activation and altered cell-cycle progression. The authors noted that ROS protection plateaued at lower concentrations while cell-cycle effects continued at higher ones, and read that dissociation as evidence for a mechanism beyond simple antioxidant chemistry.

Acute hypobaric hypoxia in rats. A 2008 report in Doklady Biological Sciences compared four regulatory peptides, including Pinealon, in male Wistar rats exposed to acute hypobaric hypoxia in an altitude chamber. Outcomes were time to respiratory arrest, posture recovery time and restitution period; Pinealon-treated animals were reported to take substantially longer to reach respiratory arrest than controls. This is a whole-animal tolerance assay in a small acute-stress model, not a measure of neuronal survival.

Amyloid pathology in transgenic mice. A 2021 paper in Pharmaceuticals tested EDR and KED in 5xFAD-M mice, a cross of the 5xFAD amyloid model with an M-line reporter. EDR was reported to increase dendritic spine density by about 11 percent. The long-term potentiation results for the companion peptide were described as a positive trend that did not reach statistical significance, and the authors reported sex differences in the spine-morphology response. Per-group sample sizes were not clearly stated in the text we retrieved.

Aged human neurons in vitro. A 2024 paper in the International Journal of Molecular Sciences transdifferentiated dermal fibroblasts from donors aged 61–68 into induced cortical neurons and applied EDR, KED and AEDG. Reported effects included increased dendritic branching and, for EDR, a roughly 23 percent reduction in oxidative DNA damage. The authors were explicit about the limits — three fibroblast lines, no significant effects on mitochondrial or lysosomal activity or on p16 and lamin B1, results framed as preliminary. That candour is to the paper's credit.

Serotonin-pathway expression. The 2014 Bulletin of Experimental Biology and Medicine study described above, in aging brain-cortex cell cultures.

Prenatal hyperhomocysteinemia. A 2012 report in the International Journal of Clinical and Experimental Medicine is titled “Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.” We located the bibliographic record but could not retrieve the full text, so we describe it here only as existing and do not characterise its findings.

One independent signal. The most interesting recent item is not from the originating group. A 2026 preprint from Marín-Jerez and colleagues describes a short-term assay screening five candidate longevity interventions in mice over eight weeks — 17α-estradiol, rapamycin plus Smer28, berberine plus resveratrol, sildenafil, and pinealon — and reports that pinealon showed a trend toward improved working memory in the mice without detectable adverse effects. Two caveats, neither small: the preprint has not completed peer review, and a trend in an eight-week screening assay is a signal to follow up, not a finding. It is still the closest thing to independent replication we could locate.

Pinealon vs Epithalon

These two are constantly mentioned together, so it helps to set out where they actually differ.

Researchers comparing the two typically hold Epithalon and Pinealon side by side precisely because the framework predicts they should behave differently by tissue despite sharing a mechanism — which makes them a natural pair for anyone actually trying to test the tissue-specificity claim rather than assume it.

What the evidence does not establish

This section is longer than usual for these guides, because in this case the limits are most of the story.

The literature is very small. A Europe PMC search for “Pinealon” returns 29 records in total. That is the whole indexed record for this compound. Strip out the false matches on the search string and the non-experimental reviews and you are left with under a dozen primary studies. For context, a peptide with a settled evidence base has hundreds to thousands of indexed records.

It is concentrated in one group and one venue. Of those 29 records, roughly a dozen are Russian-language articles in Advances in Gerontology, a journal with limited international circulation, and nearly every English-language experimental paper shares Vladimir Khavinson as an author. Single-group literatures are not automatically wrong — every programme starts as one group — but they are structurally unable to provide what replication is for. Systematic errors in method, reagent or analysis propagate rather than cancel.

Language and access compound the problem. A substantial fraction of the underlying work is not readable by most of the field, has not been independently re-analysed, and in several cases full texts are not retrievable at all. That is not a claim that the Russian-language work is poor. It is a claim that it is effectively unaudited.

Mechanism is modelled more than measured. Much of the gene-regulatory case rests on docking and homology modelling — predicting that a peptide could bind a promoter or a histone. Prediction is a legitimate first step, but it is not occupancy data, and the field has a long history of docking predictions that did not survive testing.

Key steps are assumed rather than shown. Uptake of ultrashort peptides is described by the originating group's own 2022 review as not properly studied. Nuclear entry evidence comes largely from labelled peptides in a cancer cell line. Neither has been demonstrated for unlabelled Pinealon in the neuronal tissue it is proposed to act on.

Effect sizes are small and models are narrow. An 11 percent change in dendritic spine density in a transgenic mouse and a 23 percent change in an oxidative DNA damage marker across three donor cell lines are modest effects in narrow systems. The 2024 paper found no effect on several other aging markers it measured, which is useful information and is easy to lose when only the positive readouts get repeated.

Negative and null results are largely invisible. Across this literature we found very few reported failures. In a small single-group body of work, that pattern is more likely to reflect publication practice than a genuinely high hit rate.

Nothing here supports use in people. There are no adequate, controlled human trials for Pinealon and no regulatory approval in any major jurisdiction. The Russian-language items describing peptide effects in human cohorts are small, mostly unblinded and not independently replicated. Nothing in this guide should be read as suggesting an application in humans or animals.

Bench context

Pinealon is supplied as a lyophilised powder, and is handled by the same general principles as anything else in a vial. One point is specific to very short peptides: analytical characterisation is comparatively easy at this size, since a tripeptide gives a clean, unambiguous mass spectrum. There is correspondingly little excuse for missing identity data, and the certificate of analysis should show an unambiguous mass match alongside a purity figure.

Researchers in this area often look at Pinealon alongside the more conventionally studied neuroactive compounds covered in our roundup of peptides studied for cognition, and sleep-associated peptides such as DSIP — which shares with Pinealon the awkward distinction of being widely discussed on a thinner published record than its reputation suggests.

Frequently asked questions

Is Pinealon the same thing as the EDR peptide? Yes. Pinealon is the commercial name; EDR — the one-letter abbreviation of Glu-Asp-Arg — is what the primary literature usually calls it. Searching under only one of the two names will give you an incomplete picture of the research.

Does Pinealon come from the pineal gland? The name suggests it, but a 2021 Molecules review describes EDR as having been isolated from Cortexin, a cortex-derived preparation. Within the bioregulator framework it is assigned to brain tissue generally rather than to the pineal gland specifically — the pineal peptide in that family is Epithalon.

Is the DNA-binding mechanism proven? No. There is physicochemical work on the Glu-Asp-Arg–DNA interaction and a good deal of molecular modelling predicting binding sites in specific promoters, but predicted binding is not measured occupancy, and no independent study we could locate demonstrates the full proposed chain from uptake through transcriptional change.

Why is a tripeptide's specificity questioned? Because there are only 8,000 possible tripeptides and this particular string occurs commonly inside ordinary proteins and is released routinely by proteolysis. Explaining how a motif that common could drive a specific, tissue-restricted transcriptional programme is the mechanistic burden this framework carries.

Has anyone outside the originating group tested it? Barely. The clearest example is a 2026 preprint in which an independent laboratory included pinealon among five candidate longevity interventions in an eight-week mouse screening assay and reported a trend toward improved working memory with no detectable adverse effects. It is a preprint, it has not completed peer review, and a trend is not a result — but it is genuinely independent, which nothing else here is.

Is Pinealon approved for human use? No. It is not an approved drug in the United States and is sold strictly for in-vitro research and laboratory use only, not for human or veterinary consumption.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.